Skip to main content
Erschienen in: Journal of Clinical Immunology 3/2015

01.04.2015 | Original Research

The Duesseldorf Warning Signs for Primary Immunodeficiency: Is it Time to Change the Rules?

verfasst von: Petra Lankisch, Julia Schiffner, Sujal Ghosh, Florian Babor, Arndt Borkhardt, Hans-Jürgen Laws

Erschienen in: Journal of Clinical Immunology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

Different sets of warning signs can be used if primary immunodeficiency (PID) is suspected: those of the Jeffrey Modell Foundation (JMF), the German Patients’ Organisation for Primary Immunodeficiencies (DSAI) and the Association of the Scientific Medical Societies in Germany (AWMF). A few studies have tested the JMF criteria, with unconvincing results, but the diagnostic models of the DSAI and AWMF have not been tested at all. We set out to establish the utility of these three scoring systems and compare them with our own set of five warning signs (Duesseldorf criteria).

Design

Prospective study.

Patients

Two hundred ten patients admitted to our hospital between 2010 and 2012 with suspected PID.

Results

PID were found in 36 (17 %) of the patients admitted. Of the established sets of warning signs, the JMF and the DSAI had inadequate sensitivity, while the DSAI and the AWMF showed insufficient specificity. Our own criteria were analyzed with regard to maximal specificity and sensitivity (Youden Index) and sensitivity and yielded NPV of 0.89 and 0.91 respectively. Youden index revealed combination of five signs and symptoms: lymphopenia, otitis media >7, failure to thrive, failure to grow normally, pneumonia >1. For maximum negative predictive value the following set was found: lymphopenia, hypogammglobulinemia, failure to thrive, growth disorders, iv antibiotics and abscesses.

Conclusion

In contrast to the new, evaluated Duesseldorf criteria, all three established sets of warning signs proved inadequate for preselection of patients for admission to specialized PID centers. The Duesseldorf criteria should now being tested in further studies.
Literatur
1.
Zurück zum Zitat Gathmann B, Grimbacher B, Beaute J, Dudoit Y, Mahlaoui N, Fischer A, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006–2008. Clin Exp Immunol. 2009;157 Suppl 1:3–11.CrossRefPubMedCentralPubMed Gathmann B, Grimbacher B, Beaute J, Dudoit Y, Mahlaoui N, Fischer A, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006–2008. Clin Exp Immunol. 2009;157 Suppl 1:3–11.CrossRefPubMedCentralPubMed
2.
Zurück zum Zitat Al-Tamemi S, Elnour I, Dennison D. Primary immunodeficiency diseases in Oman: five years’ experience at sultan qaboos university hospital. World Allergy Organ J. 2012;5(5):52–6.CrossRefPubMedCentralPubMed Al-Tamemi S, Elnour I, Dennison D. Primary immunodeficiency diseases in Oman: five years’ experience at sultan qaboos university hospital. World Allergy Organ J. 2012;5(5):52–6.CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat Ehlayel MS, Bener A, Laban MA. Primary immunodeficiency diseases in children: 15 year experience in a tertiary care medical center in Qatar. J Clin Immunol. 2013;33(2):317–24.CrossRefPubMed Ehlayel MS, Bener A, Laban MA. Primary immunodeficiency diseases in children: 15 year experience in a tertiary care medical center in Qatar. J Clin Immunol. 2013;33(2):317–24.CrossRefPubMed
4.
Zurück zum Zitat Arkwright PD, Gennery AR. Ten warning signs of primary immunodeficiency: a new paradigm is needed for the 21st century. Ann N Y Acad Sci. 2011;1238:7–14.CrossRefPubMed Arkwright PD, Gennery AR. Ten warning signs of primary immunodeficiency: a new paradigm is needed for the 21st century. Ann N Y Acad Sci. 2011;1238:7–14.CrossRefPubMed
5.
Zurück zum Zitat Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497–502.CrossRefPubMed Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497–502.CrossRefPubMed
6.
Zurück zum Zitat Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.CrossRefPubMed Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.CrossRefPubMed
8.
Zurück zum Zitat Joshi AY, Iyer VN, Hagan JB, St Sauver JL, Boyce TG. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc Mayo Clin. 2009;84(1):16–22.CrossRef Joshi AY, Iyer VN, Hagan JB, St Sauver JL, Boyce TG. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc Mayo Clin. 2009;84(1):16–22.CrossRef
9.
Zurück zum Zitat Mohammadinejad P, Mirminachi B, Sadeghi B, Movahedi M, Gharagozlou M, Mohammadi J, et al. Distribution of primary immunodeficiency disorders diagnosed in a tertiary referral center, Tehran, Iran (2006–2013). Iran J Immunol IJI. 2014;11(4):282–91. Mohammadinejad P, Mirminachi B, Sadeghi B, Movahedi M, Gharagozlou M, Mohammadi J, et al. Distribution of primary immunodeficiency disorders diagnosed in a tertiary referral center, Tehran, Iran (2006–2013). Iran J Immunol IJI. 2014;11(4):282–91.
10.
Zurück zum Zitat Michos A, Raptaki M, Tantou S, Tzanoudaki M, Spanou K, Liatsis M, et al. Primary immunodeficiency diseases: a 30-year patient registry from the referral center for primary immunodeficiencies in Greece. J Clin Immunol. 2014;34(7):836–43.CrossRefPubMed Michos A, Raptaki M, Tantou S, Tzanoudaki M, Spanou K, Liatsis M, et al. Primary immunodeficiency diseases: a 30-year patient registry from the referral center for primary immunodeficiencies in Greece. J Clin Immunol. 2014;34(7):836–43.CrossRefPubMed
11.
Zurück zum Zitat Gathmann B, Goldacker S, Klima M, Belohradsky BH, Notheis G, Ehl S, et al. The German national registry for primary immunodeficiencies (PID). Clin Exp Immunol. 2013;173(2):372–80.CrossRefPubMedCentralPubMed Gathmann B, Goldacker S, Klima M, Belohradsky BH, Notheis G, Ehl S, et al. The German national registry for primary immunodeficiencies (PID). Clin Exp Immunol. 2013;173(2):372–80.CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Wood P, Stanworth S, Burton J, Jones A, Peckham DG, Green T, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol. 2007;149(3):410–23.CrossRefPubMedCentralPubMed Wood P, Stanworth S, Burton J, Jones A, Peckham DG, Green T, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol. 2007;149(3):410–23.CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Carneiro-Sampaio M, Jacob CM, Leone CR. A proposal of warning signs for primary immunodeficiencies in the first year of life. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2011;22(3):345–6.CrossRef Carneiro-Sampaio M, Jacob CM, Leone CR. A proposal of warning signs for primary immunodeficiencies in the first year of life. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2011;22(3):345–6.CrossRef
16.
Zurück zum Zitat Farmand S, Baumann U, von Bernuth H, Borte M, Foerster-Waldl E, Franke K, et al. Interdisciplinary AWMF guideline for the diagnostics of primary immunodeficiency. Klin Padiatr. 2011;223(6):378–85.CrossRefPubMed Farmand S, Baumann U, von Bernuth H, Borte M, Foerster-Waldl E, Franke K, et al. Interdisciplinary AWMF guideline for the diagnostics of primary immunodeficiency. Klin Padiatr. 2011;223(6):378–85.CrossRefPubMed
17.
Zurück zum Zitat MacGinnitie A, Aloi F, Mishra S. Clinical characteristics of pediatric patients evaluated for primary immunodeficiency. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2011;22(7):671–5.CrossRef MacGinnitie A, Aloi F, Mishra S. Clinical characteristics of pediatric patients evaluated for primary immunodeficiency. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2011;22(7):671–5.CrossRef
18.
Zurück zum Zitat Subbarayan A, Colarusso G, Hughes SM, Gennery AR, Slatter M, Cant AJ, et al. Clinical features that identify children with primary immunodeficiency diseases. Pediatrics. 2011;127(5):810–6.CrossRefPubMed Subbarayan A, Colarusso G, Hughes SM, Gennery AR, Slatter M, Cant AJ, et al. Clinical features that identify children with primary immunodeficiency diseases. Pediatrics. 2011;127(5):810–6.CrossRefPubMed
19.
Zurück zum Zitat Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014;5:162.PubMedCentralPubMed Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014;5:162.PubMedCentralPubMed
20.
Zurück zum Zitat Lankisch P, Borkhardt A, Pfründer D, Laws H-J. What lies behind the referral diagnosis “e.g. an immune defect?”. Monatsschr Kinderheilkd. 2014;162:146–9.CrossRef Lankisch P, Borkhardt A, Pfründer D, Laws H-J. What lies behind the referral diagnosis “e.g. an immune defect?”. Monatsschr Kinderheilkd. 2014;162:146–9.CrossRef
21.
Zurück zum Zitat Moskowitz CS, Pepe MS. Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs. Clin Trials. 2006;3(3):272–9.CrossRefPubMed Moskowitz CS, Pepe MS. Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs. Clin Trials. 2006;3(3):272–9.CrossRefPubMed
22.
Zurück zum Zitat Bloch DA. Comparing two diagnostic tests against the same “gold standard” in the same sample. Biometrics. 1997;53(1):73–85.CrossRefPubMed Bloch DA. Comparing two diagnostic tests against the same “gold standard” in the same sample. Biometrics. 1997;53(1):73–85.CrossRefPubMed
23.
Zurück zum Zitat Reda SM, El-Ghoneimy DH, Afifi HM. Clinical predictors of primary immunodeficiency diseases in children. Allergy Asthma Immunol Res. 2013;5(2):88–95.CrossRefPubMedCentralPubMed Reda SM, El-Ghoneimy DH, Afifi HM. Clinical predictors of primary immunodeficiency diseases in children. Allergy Asthma Immunol Res. 2013;5(2):88–95.CrossRefPubMedCentralPubMed
Metadaten
Titel
The Duesseldorf Warning Signs for Primary Immunodeficiency: Is it Time to Change the Rules?
verfasst von
Petra Lankisch
Julia Schiffner
Sujal Ghosh
Florian Babor
Arndt Borkhardt
Hans-Jürgen Laws
Publikationsdatum
01.04.2015
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 3/2015
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-015-0149-1

Weitere Artikel der Ausgabe 3/2015

Journal of Clinical Immunology 3/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.